Publications by authors named "Feiguang Long"
Background And Objectives: The high costs associated with biological agents often limit accessibility for many patients, whereas biosimilars allow the wider application of biological treatment. The objectives of this phase I clinical trial were to compare the pharmacokinetics, immunogenicity, and safety profiles of the biosimilar adalimumab-WIBP and the reference product Humira and to assess the precision of the bioequivalence evaluation.
Methods: In this randomized, double-blind, parallel-group bioequivalence study, 164 healthy male Chinese participants were selected and randomly divided into two groups on a 1:1 ratio.
Article Synopsis
- The study explored the use of F61 nasal spray, a broad-spectrum neutralizing antibody, as an alternative method to manage the Omicron COVID-19 variants in China amid a shift from a strict zero-COVID strategy from late 2022 to early 2023.
- In a trial with 2,008 participants, those using F61 showed lower rates of SARS-CoV-2 infections in the multiple-dose group compared to the placebo, demonstrating significant efficacy.
- Real-world application of F61 among over 60,000 volunteers indicated over 90% efficacy against Omicron variants, highlighting its potential as a safe and effective prophylactic treatment against COVID-19.